Blue Latitude Health’s consultancy is based on a rich vein of expert knowledge. Here you’ll find thought-provoking commentary, articles, and downloadable resources created by our consultants.
Explore our ideas and get a deeper understanding of the current and future trends in healthcare:
|16th November 2016
Account Executive Victoria Morton explores what it’s like to live with Crohn’s disease as a young person, and investigates what’s being done to tackle the gaps in treatment options for patients.
|6th October 2016
Managing Director Martin Brass discusses what a reverse auction is, and whether it truly is a good way for healthcare companies to drive efficiencies when procuring marketing services.
|30th September 2016
Creative Director Damien Parsonage breaks down the common misconception that pharma and healthcare marketing for healthcare professionals ought to be entirely scientific and rational. Brands are powerful; here's how to strengthen yours by infusing it with emotion.
|26th September 2016
The age of computers has hugely evolved, and with the emergence of effective machine learning, pattern recognition, and decision-making algorithms, Artificial Intelligence provides a revolutionary new approach to tailored healthcare. Associate Medical Copywriter Kulveer Singh dives deeper into the technology.
|19th September 2016
Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through what this means for pharma strategists and their product lines.
|14th September 2016
Senior Account Executive Dave Wood talks us through what DAM and CMS are, the role they play in the future of healthcare marketing, and how they can be best utilised to maximise outcomes for pharma and agencies.
|2nd September 2016
Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer's disease.
|24th August 2016
In this article, Associate Consultant Louis Perdios talks about the immunotherapy drug Opdivo and the daunting challenges faced by BMS after disappointing results. However the future for Opdivo may not be as bleak as it seems.
|18th August 2016
What do the new immunotherapies in oncology mean for those stakeholders who need to understand and make decisions about treatment? Even more importantly, what do immunotherapies mean for patients who face diagnosis of advanced cancers? Senior Associate Consultants Frances Hendry and Zoe Bartley tackle these complex questions.